CCA
TCRR

Catalyst Capital Advisors’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Catalyst Capital Advisors’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-459
Closed -$7K – 500
2019
Q2 		$7K Hold
459
– – ﹤0.01% 361
2019
Q1 		$8K Buy
+459
New +$8.14K ﹤0.01% 318

Other funds holding TCRR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Catalyst Capital Advisors's TCRR Position: Q3 2019 in Review

Catalyst Capital Advisors sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q3 2019, closing a stake of 459 shares — an estimated $7K sold.

Catalyst Capital Advisors first reported a position in TCRR in Q1 2019 and held it in 2 quarters. The position peaked at $8K in Q1 2019. 40 funds tracked by Wall St. Rank hold TCRR as of Q3 2019.

  • Catalyst Capital Advisors reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
  • Catalyst Capital Advisors sold 459 TCR2 Therapeutics Inc. Common Stock shares in Q3 2019, an estimated $7K.
  • Catalyst Capital Advisors first reported a position in TCR2 Therapeutics Inc. Common Stock in Q1 2019 and held it in 2 quarters.
  • Catalyst Capital Advisors's TCR2 Therapeutics Inc. Common Stock position peaked at $8K in Q1 2019.
  • 40 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q3 2019.

Based on Catalyst Capital Advisors's 13F filing for Q3 2019, filed 5 Nov 2019.